CRDL Stock Overview
A clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Cardiol Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$2.00 |
| 52 Week High | CA$3.12 |
| 52 Week Low | CA$0.66 |
| Beta | 0.63 |
| 11 Month Change | -23.66% |
| 3 Month Change | 10.50% |
| 1 Year Change | 123.44% |
| 33 Year Change | -17.36% |
| 5 Year Change | -39.14% |
| Change since IPO | -46.55% |
Recent News & Updates
Recent updates
Shareholder Returns
| CRDL | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | -1.2% | -0.06% |
| 1Y | 123.4% | 18.1% | 20.5% |
Return vs Industry: CRDL exceeded the US Pharmaceuticals industry which returned 18.1% over the past year.
Return vs Market: CRDL exceeded the US Market which returned 20.5% over the past year.
Price Volatility
| CRDL volatility | |
|---|---|
| CRDL Average Weekly Movement | 13.3% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: CRDL's share price has been volatile over the past 3 months.
Volatility Over Time: CRDL's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | n/a | David Elsley | www.cardiolrx.com |
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure.
Cardiol Therapeutics Inc. Fundamentals Summary
| CRDL fundamental statistics | |
|---|---|
| Market cap | US$135.81m |
| Earnings (TTM) | -US$21.99m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-6.2x
P/E RatioIs CRDL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CRDL income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$30.22m |
| Earnings | -CA$30.22m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.44 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CRDL perform over the long term?
See historical performance and comparison